カテゴリ： GlobalData, 医療/バイオ

家族性高コレステロール血症（II型高リポタンパク血症）治療薬の世界市場：治験レビュー

◆英語タイトル：Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019
◆商品コード：GDT20FB0039
◆発行会社（リサーチ会社）：GlobalData
◆発行日：2019年12月
◆ページ数：304
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,500 ⇒換算￥275,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD5,000 ⇒換算￥550,000見積依頼/購入/質問フォーム
Enterprisewide Price（複数事業所内共有可）USD7,500 ⇒換算￥825,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

 【レポートの概要】

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019
Summary

GlobalData’s clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019″ provides an overview of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 17
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 20
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials 30
Prominent Drugs 31
Latest Clinical Trials News on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) 32
Nov 11, 2019: Amgen highlights data to be presented on Repatha at AHA 2019 Across Cardiovascular Portfolio 32
Nov 06, 2019: The Medicines company to present inclisiran data from ORION-9 and ORION-10 pivotal phase 3 clinical studies at American Heart Association Scientific Sessions 2019 33
Sep 17, 2019: Arrowhead reports initial data for cardiometabolic candidates 33
Sep 16, 2019: Arrowhead Pharmaceuticals presents initial top-line clinical data and preclinical data on RNAi Candidate ARO-APOC3 34
Clinical Trial Profile Snapshots 35
Appendix 303
Abbreviations 303
Definitions 303
Research Methodology 304
Secondary Research 304
About GlobalData 305
Contact Us 305
Source 306

List of Tables
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region, 2019* 8
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 15
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019* 17
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 18
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 19
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019* 20
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 21
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 22
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase, 2019* 23
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 24
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 25
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 26
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 27
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 28
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 29
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 30
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 31

List of Figures
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019* 15
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019* 17
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 18
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 19
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019* 20
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 21
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 22
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 23
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 24
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 25
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 26
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 27
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 28
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 29
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 30
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 31
GlobalData Methodology 304

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[家族性高コレステロール血症（II型高リポタンパク血症）治療薬の世界市場：治験レビュー]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. 血友病B（第IX因子欠乏症）治療薬の世界市場：治験レビュー
    GDT20FB0040 / GlobalData / 2019年12月 / ...Hemophilia B (Factor IX Deficiency) Global Clinical Trials Review, H2, 2019 Summary GlobalData's clinical trial report, “Hemophilia B (Factor IX Deficiency) Global Clinical Trials Review, H2, 2019" provides an overview of Hemophilia B (Factor IX Deficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia B (Factor IX Deficiency) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also...
  2. シッカ症候群（シェーグレン）治療薬の世界市場：治験レビュー
    GDT20FB0045 / GlobalData / 2019年12月 / ...Sicca Syndrome (Sjogren) Global Clinical Trials Review, H2, 2019 Summary GlobalData's clinical trial report, “Sicca Syndrome (Sjogren) Global Clinical Trials Review, H2, 2019" provides an overview of Sicca Syndrome (Sjogren) clinical trials scenario. This report provides top line data relating to the clinical trials on Sicca Syndrome (Sjogren) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on...
  3. 腎臓がん（腎細胞がん）治療薬の世界市場：治験レビュー
    GDT20FB0101 / GlobalData / 2020年1月 / ...Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, “Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H1, 2020" provides an overview of Kidney Cancer (Renal Cell Cancer) Clinical trials scenario. This report provides top line data relating to the clinical trials on Kidney Cancer (Renal Cell Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides...
  4. レーバー遺伝性視神経障害（レーバー視神経萎縮）治療薬の世界市場：治験レビュー
    GDT20FB0036 / GlobalData / 2019年12月 / ...Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) Global Clinical Trials Review, H2, 2019 Summary GlobalData's clinical trial report, “Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Global Clinical Trials Review, H2, 2019" provides an overview of Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) clinical trials scenario. This report provides top line data relating to the clinical trials on Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status,...
  5. 末梢T細胞リンパ腫（PTCL）治療薬の世界市場：治験レビュー
    GDT20FB0005 / GlobalData / 2019年12月 / ...Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H2, 2019 Summary GlobalData's clinical trial report, “Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H2, 2019" provides an overview of Treatment Peripheral T-Cell Lymphomas (PTCL) clinical trials scenario. This report provides top line data relating to the clinical trials on Peripheral T-Cell Lymphomas (PTCL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...
  6. 注意欠陥多動性障害（ADHD）治療薬の世界市場：治験レビュー
    GDT20FB0028 / GlobalData / 2019年12月 / ...Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, 2019 Summary GlobalData's clinical trial report, “Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, 2019" provides an overview of Attention Deficit Hyperactivity Disorder (ADHD) clinical trials scenario. This report provides top line data relating to the clinical trials on Attention Deficit Hyperactivity Disorder (ADHD)Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
  7. 神経障害性疼痛（神経痛）治療薬の世界市場：治験レビュー
    GDT20FB0061 / GlobalData / 2019年12月 / ...Neuropathic Pain (Neuralgia) Global Clinical Trials Review, H2, 2019 Summary GlobalData's clinical trial report, “Neuropathic Pain (Neuralgia) Global Clinical Trials Review, H2, 2019" provides an overview of Neuropathic Pain (Neuralgia) clinical trials scenario. This report provides top line data relating to the clinical trials on Neuropathic Pain (Neuralgia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number...
  8. 末期腎疾患（末期腎疾患またはESRD）治療薬の世界市場：治験レビュー
    GDT20FB0106 / GlobalData / 2020年1月 / ...End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, “End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Global Clinical Trials Review, H1, 2020" provides an overview of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Clinical trials scenario. This report provides top line data relating to the clinical trials on End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7),...
  9. 消化管間質腫瘍（GIST）治療薬の世界市場：治験レビュー
    GDT20FB0006 / GlobalData / 2019年12月 / ...Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H2, 2019 Summary GlobalData's clinical trial report, “Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H2, 2019" provides an overview of Treatment Gastrointestinal Stromal Tumor (GIST) clinical trials scenario. This report provides top line data relating to the clinical trials on Gastrointestinal Stromal Tumor (GIST). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆